NASDAQ:CCXI ChemoCentryx (CCXI) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free CCXI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$51.99▼$51.9950-Day Range$51.66▼$51.9952-Week Range$14.95▼$52.00Volume113 shsAverage Volume1.68 million shsMarket Capitalization$3.71 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ChemoCentryx alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About ChemoCentryx Stock (NASDAQ:CCXI)ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. CCXI Stock News HeadlinesFebruary 22, 2024 | benzinga.comRishi Gupta's Net WorthOctober 20, 2022 | prnewswire.comAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX - PR NewswireApril 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…October 20, 2022 | finance.yahoo.comAMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYXOctober 17, 2022 | finance.yahoo.comChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings - Yahoo FinanceOctober 17, 2022 | finance.yahoo.comChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual MeetingsOctober 15, 2022 | nasdaq.comChemoCentryx Inc Shares Close in on 52-Week High - Market Mover - NasdaqOctober 7, 2022 | nasdaq.comChemoCentryx Inc Shares Approach 52-Week High - Market Mover - NasdaqApril 24, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…October 6, 2022 | nasdaq.comIs ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year? - NasdaqOctober 6, 2022 | finance.yahoo.comIs ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?October 5, 2022 | globenewswire.comChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewswireOctober 5, 2022 | finance.yahoo.comChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingSeptember 30, 2022 | fool.comChemoCentryx (NASDAQ: CCXI)September 24, 2022 | thestreet.comBiotech Valuations Remain In a Slump - TheStreetSeptember 19, 2022 | gurufocus.comAmgen CEO Sees Tougher Sleddin - GuruFocus.comSeptember 19, 2022 | investors.comThese 10 Biotech Stocks Would Have Netted You $10000 More This Year - Investor's Business DailySeptember 15, 2022 | nasdaq.comSPDR S&P Biotech ETF Experiences Big Inflow - NasdaqSeptember 14, 2022 | seekingalpha.comAmgen (AMGN): Growing Doubts About The Future - Seeking AlphaSeptember 13, 2022 | stockhouse.com2022-09-13 | NDAQ:CCXI | Press Release | ChemoCentryx Inc. - StockhouseSeptember 13, 2022 | businesswire.comINVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.'s Directors and Officers for Breach of Fiduciary Duties – CCXI - Business WireSeptember 13, 2022 | benzinga.comChemoCentryx (NASDAQ:CCXI) – INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCent - BenzingaSeptember 13, 2022 | seekingalpha.comAmgen Stock Is Looking Interesting On The Dip (NASDAQ:AMGN) - Seeking AlphaSeptember 7, 2022 | nasdaq.comWhy Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report? - NasdaqSeptember 7, 2022 | finance.yahoo.comWhy Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?September 5, 2022 | reuters.comCCXI.N - ChemoCentryx Inc | Stock Price & Latest News | ReutersSeptember 4, 2022 | reuters.comCCXI.O - ChemoCentryx Inc | Stock Price & Latest News | ReutersSee More Headlines Receive CCXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:CCXI CUSIP16383L10 CIK1340652 Webwww.chemocentryx.com Phone(650) 210-2900Fax650-210-2910Employees178Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,760,000.00 Net Margins-357.01% Pretax Margin-357.01% Return on Equity-48.52% Return on Assets-30.59% Debt Debt-to-Equity Ratio0.02 Current Ratio4.54 Quick Ratio4.47 Sales & Book Value Annual Sales$32.22 million Price / Sales115.14 Cash FlowN/A Price / Cash FlowN/A Book Value$4.09 per share Price / Book12.71Miscellaneous Outstanding Shares71,356,000Free Float65,433,000Market Cap$3.71 billion OptionableOptionable Beta1.22 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Thomas J. Schall Ph.D. (Age 63)Founder, Pres, CEO & Chairman Comp: $1.21MMs. Susan M. Kanaya (Age 59)Exec. VP, Chief Financial & Admin. Officer, Sec. and Director Comp: $845.04kMr. Tausif Butt (Age 56)Exec. VP & COO Comp: $1.01MDr. Rita I. Jain M.D. (Age 59)Exec. VP, Chief Medical Officer & Exec. Employee Director Comp: $670.7kDr. Markus J. Cappel Ph.D. (Age 61)Chief Bus. Officer & Treasurer Comp: $643.58kMs. Yi Ching Yau (Age 46)Sr. VP of Fin. & Principal Accounting Officer Mr. William S. SlatteryVP of Investor Relations & Corp. CommunicationsMs. Kari E. LeetchSr. VP of HRDr. Sangita Ghosh Ph.D.Sr. VP of Technical OperationsMore ExecutivesKey CompetitorsAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDMadrigal PharmaceuticalsNASDAQ:MDGLGeronNASDAQ:GERNDynavax TechnologiesNASDAQ:DVAXView All Competitors CCXI Stock Analysis - Frequently Asked Questions How were ChemoCentryx's earnings last quarter? ChemoCentryx, Inc. (NASDAQ:CCXI) issued its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.13. The biopharmaceutical company earned $17.74 million during the quarter, compared to the consensus estimate of $14.70 million. ChemoCentryx had a negative trailing twelve-month return on equity of 48.52% and a negative net margin of 357.01%. During the same period last year, the company earned ($0.35) earnings per share. What is Thomas J. Schall's approval rating as ChemoCentryx's CEO? 21 employees have rated ChemoCentryx Chief Executive Officer Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among the company's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 44.0% of employees surveyed would recommend working at ChemoCentryx to a friend. What other stocks do shareholders of ChemoCentryx own? Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Advanced Micro Devices (AMD) and Arrowhead Pharmaceuticals (ARWR). This page (NASDAQ:CCXI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChemoCentryx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
